Literature DB >> 1444788

Management of small soft-tissue sarcoma of the extremity in adults.

R J Geer1, J Woodruff, E S Casper, M F Brennan.   

Abstract

To determine the significance of small (< or = 5 cm in diameter) soft-tissue sarcoma of the extremity, 174 adult patients were identified from information that had been entered prospectively into a database of 1742 patients between July 1982 and December 1990. Median follow-up was 48 months. The majority of tumors were high grade (n = 114; 66%). Local recurrence (n = 17) was seen in patients with both high-grade (11%) and low-grade tumors (7%). Distant metastases were seen in 7% of high-grade tumors and in no low-grade tumors. The overall 5-year survival rate was 94% for all patients. Grade, depth, location, type of operation, and sex did not affect 5-year survival or local recurrence-free survival. Neither postoperative adjuvant chemotherapy nor radiation therapy resulted in superior 5-year survival or local recurrence-free survival when compared with no postoperative treatment. The prognosis of these lesions is favorable, and no additional prognostic factors were identified. Inclusion of these patients into adjuvant therapy trials examining survival is inappropriate.

Entities:  

Mesh:

Year:  1992        PMID: 1444788     DOI: 10.1001/archsurg.1992.01420110027007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  19 in total

1.  Soft tissue sarcoma clinical practice guidelines in oncology.

Authors:  George D Demetri; Laurence H Baker; Derrick Beech; Robert Benjamin; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; David S Ettinger; Martin J Heslin; Ray J Hutchinson; Krystyna Kiel; William G Kraybill; G Douglas Letson; James Neff; Richard J O'Donnell; I Benjamin Paz; Raphael E Pollock; R Lor Randall; Karen D Schupak; Douglas S Tyler; Margaret von Mehren; Jeffrey Wayne
Journal:  J Natl Compr Canc Netw       Date:  2005-03       Impact factor: 11.908

2.  Compartmental resection for subfascial extremity soft tissue sarcoma and quality of life in long-term survivors.

Authors:  Matthias Peiper; Hanno Matthaei; Edwin Bölke; David Zurakowski; Klaus Orth; Antje Heinecke; Wolfram Trudo Knoefel
Journal:  Wien Klin Wochenschr       Date:  2011-07-12       Impact factor: 1.704

3.  Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma.

Authors:  S Singer; J M Corson; R Gonin; B Labow; T J Eberlein
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

4.  Clinicopathological study and management of peripheral soft tissue tumours.

Authors:  Abhijit Mohan Gogi; Ranjani Ramanujam
Journal:  J Clin Diagn Res       Date:  2013-09-27

Review 5.  Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma.

Authors:  M A Gadd; E S Casper; J M Woodruff; P M McCormack; M F Brennan
Journal:  Ann Surg       Date:  1993-12       Impact factor: 12.969

6.  Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.

Authors:  S Singer; J M Corson; G D Demetri; E A Healey; K Marcus; T J Eberlein
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

7.  Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience.

Authors:  J N Vauthey; J M Woodruff; M F Brennan
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

8.  [Soft-tissue sarcoma of the forearm and hand. Plastic surgical management].

Authors:  M Müller; B Bickert; G Germann; M Sauerbier
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

9.  [Local recurrence of soft tissue sarcoma of the extremities and trunk].

Authors:  M Peiper; D Zurakowski; C Zornig
Journal:  Langenbecks Arch Chir       Date:  1995

10.  Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Doris Quon; Andreh Saralou; William C Blackwelder; Frederick L Hall; Erlinda M Gordon
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.